Carlo M Ong

Sep 26, 2024 | biorxiv.org | Kentson Lam |Yoon Kim |Andrea Liu |Carlo M Ong

AbstractOncogenic growth places great strain and dependence on the proteostasis network. This has made proteostasis pathways attractive therapeutic targets in cancer, but efforts to drug these pathways have yielded disappointing clinical outcomes. One exception is proteasome inhibitors, which are approved for frontline treatment of multiple myeloma.